Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDavid Ross

Discussion

Loading...

Member takes

Overview

Registry analysis shows that KMI selection influences treatment-free remission eligibility and outcomes in chronic myeloid leukemia patients.

Key Points

  • Treatment-free remission eligibility differs significantly based on the selected tyrosine kinase inhibitor and patient gender.
  • The median follow up for the analyzed patients was 8.1 years, revealing critical trends in treatment cessation and remission.
  • Cumulative incidence rates over 12 years highlight the stark differences in outcomes between first and second-generation tyrosine kinase inhibitors.
  • Continued analysis of treatment outcomes is essential for optimizing chronic myeloid leukemia management strategies.

Cite This Study

David Ross (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e12fhttps://doi.org/10.1182/blood-2025-2008
View Full Paper
Ask AI
Bookmark
Share